Nanobiotix posts 70% 1-year survival in Phase 1 lung study

Nanobiotix released full Phase 1 NSCLC re-irradiation data for JNJ-1900 (NBTXR3), showing high one-year tumor control with no dose-limiting toxicities and a defined Phase 2 dose.

Rhea-AI Filing Summary

Nanobiotix S.A. (NBTX) reported full Phase 1 cohort results for radiotherapy-activated JNJ-1900 (NBTXR3) in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation. All patients completed treatment with no dose-limiting toxicities and no Grade 3 or higher adverse events related to JNJ-1900 or the injection procedure, and intratumoral injection was deemed feasible.

At a median follow-up of 12 months, one-year locoregional control was 79%, one-year local progression-free survival was 61% (median 13.6 months), and one-year overall survival was 70% (median 14.8 months), achieved with re-irradiation doses lower than patients’ prior radiotherapy. Grade 3 radiotherapy-related adverse events occurred in 33% of patients and Grade 5 radiotherapy-related events in 8%. Investigators set the recommended Phase 2 dose at 33% of gross tumor volume and concluded JNJ-1900 (NBTXR3) may support clinically meaningful local control at substantially lower re-irradiation doses, warranting evaluation in a randomized trial and further enrollment.

Key Figures

Patients treated in Phase 1 cohort: 24 patients Dose-limiting toxicities related to JNJ-1900: 0 One-year locoregional control rate: 79% +5 more

8 metrics

Patients treated in Phase 1 cohort 24 patients Inoperable, locoregionally recurrent NSCLC treated with JNJ-1900 (NBTXR3) plus re-irradiation

Dose-limiting toxicities related to JNJ-1900 0 All 24 patients completed treatment with no dose-limiting toxicities

One-year locoregional control rate 79% At median 12-month follow-up in evaluable subjects

One-year local progression-free survival 61% Median LPFS 13.6 months at data cutoff August 2026

One-year overall survival 70% Median OS 14.8 months at median 12-month follow-up

Grade 3 radiotherapy-related adverse events 33% (8 patients) Reported among 24 treated patients

Grade 5 radiotherapy-related adverse events 8% (2 patients) Reported among 24 treated patients

Recommended Phase 2 dose 33% of gross tumor volume JNJ-1900 (NBTXR3) intratumoral injection dose selection

Key Terms

locoregional control, local progression-free survival, overall survival, re-irradiation, +2 more

6 terms

locoregional control medical

"the one-year locoregional control rate was 79%"

A measure used in cancer care and clinical trials that describes how well treatment prevents a tumor and the nearby lymph nodes or tissues from growing or returning in the same area. Think of it like keeping weeds from reappearing in a specific part of a garden: locoregional control shows whether the problem is contained locally rather than spreading elsewhere. It matters to investors because strong locoregional control can indicate a therapy’s clinical benefit, affect regulatory decisions, label claims, and influence commercial prospects.

local progression-free survival medical

"One-year local progression-free survival ("LPFS") was 61%"

Time from the start of treatment or trial enrollment until the cancer visibly worsens at the original (local) tumor site or the patient dies; occurrences of new tumors elsewhere are not the primary event unless the original site progresses. It matters to investors because it measures how well a therapy or procedure controls disease at the targeted location, which can influence trial success, regulatory decisions, and commercial value—think of it like how long a repaired roof stays leak-free.

overall survival medical

"one-year overall survival ("OS") was 70%"

Overall survival is the average or median length of time patients remain alive after starting a treatment or entering a clinical study, measured regardless of cause of death. Investors care because it is a clear, hard measure of a therapy’s real-world benefit — like timing how long a new battery actually runs — and strong improvements in overall survival can drive regulatory approval, market adoption and revenue potential.

re-irradiation medical

"recurrent non-small cell lung cancer ("NSCLC") amenable to re-irradiation"

Re-irradiation is the medical practice of giving a second course of radiation therapy to a patient who previously received radiation to the same or an overlapping body area. It matters to investors because it represents a distinct clinical challenge and market niche—devices, planning software, and drugs that enable safer repeat dosing can affect treatment options, trial designs, regulatory review, reimbursement, and commercial opportunity in oncology care.

gross tumor volume medical

"The recommended Phase 2 dose was established at 33% of gross tumor volume"

Gross tumor volume (GTV) is the portion of a cancer that can be seen or felt by doctors using imaging tests or physical examination; it represents the visible, measurable mass of tumor before any treatment. Think of it as the outline of what doctors can directly detect when planning therapy. GTV matters to investors because it is used to set trial eligibility, measure tumor response, and guide treatment dosing or radiation targeting—factors that can affect clinical outcomes and regulatory assessments.

Fast Track designation regulatory

"the United States Food and Drug Administration granted regulatory Fast Track designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nanobiotix (NBTX) report in the September 2026 Phase 1 NSCLC study?

Nanobiotix reported full-cohort Phase 1 results for 24 patients with inoperable, recurrent NSCLC treated with JNJ-1900 (NBTXR3) plus re-irradiation, showing no dose-limiting toxicities, no Grade 3+ events related to JNJ-1900, and promising one-year tumor control and survival outcomes.

What were the one-year efficacy outcomes for JNJ-1900 (NBTXR3) in the NBTX Phase 1 trial?

At 12-month median follow-up, one-year locoregional control was 79%, one-year local progression-free survival was 61% with median 13.6 months, and one-year overall survival was 70% with median 14.8 months, using re-irradiation doses lower than prior radiotherapy.

What safety profile did Nanobiotix (NBTX) report for JNJ-1900 (NBTXR3) in recurrent NSCLC?

All 24 patients completed treatment with no dose-limiting toxicities and no Grade 3 or higher adverse events related to JNJ-1900 or the injection. Investigators reported Grade 3 radiotherapy-related adverse events in 33% of patients and Grade 5 radiotherapy-related events in 8%.

What dose was selected for Phase 2 in the Nanobiotix (NBTX) JNJ-1900 lung cancer study?

Investigators established the recommended Phase 2 dose of JNJ-1900 (NBTXR3) as 33% of gross tumor volume, administered via a one-time intratumoral injection activated by radiotherapy in patients undergoing re-irradiation.

How does JNJ-1900 (NBTXR3) work according to Nanobiotix (NBTX)?

JNJ-1900 (NBTXR3) consists of functionalized hafnium oxide nanoparticles injected intratumorally and activated by radiotherapy. Its mechanism is designed to induce significant tumor cell death in the injected lesion and subsequently trigger an adaptive immune response and long-term anti-cancer memory.

What are the broader development plans for JNJ-1900 (NBTXR3) mentioned by NBTX?

JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumors in Phase 1–3 studies, including MD Anderson-sponsored trials and Johnson & Johnson–led studies such as NANORAY-312, LUMIRAY, and CONVERGE, following a global license agreement with Janssen Pharmaceutica NV.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:02 AM Accepted by SEC EDGAR 09/14/2026 - 06:00 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-39777

Nanobiotix S.A.
(Translation of registrant's name into English)

60 Rue de Wattignies 75012 Paris, France
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

On September 14, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated September 14, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Nanobiotix S.A.
		(Registrant)
Date: September 14, 2026		/s/ Bart Van Rhijn
		Bart Van Rhijn
		Chief Financial Officer

EXHIBIT 99.1

NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

• All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible
• One-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapy
• Investigators concluded that JNJ-1900 (NBTXR3 may permit clinically meaningful local control using a substantially lower re-irradiation dose than patients’ prior course of radiotherapy
• Enrollment in the dose-escalation and expansion parts of the study is complete per protocol; following the encourage findings, additional patient enrollment in this study is planned

Data presented at the IASLC 2026 World Conference on Lung Cancer

PARIS and CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) evaluating radiotherapy-activated JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation (“reRT”). The data were presented by study principal investigator Saumil Gandhi, MD, PhD, at the International Association for the Study of Lung Cancer (“IASLC”) 2026 World Conference on Lung Cancer (“WCLC”), taking place September 12–15, 2026 in Seoul, Republic of Korea.

POSTER P2.260: Re-irradiation (ReRT) with NBTXR3 for Inoperable Locoregionally Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I Trial

Saumil N. Gandhi, MD, PhD; Enoch Chang, MD; Aileen B. Chen, MD; Stephen G. Chun, MD; Joe Y. Chang, MD, PhD; Steven H. Lin, MD, PhD; Matthew S. Ning, MD, MPH; David Qian, MD; Julianna K. Bronk, MD, PhD; Rahul A. Sheth, MD; Jianjun Zhang, MD, PhD; Tina Cascone, MD, PhD; Marcelo Vailati Negrao, MD; Anne S. Tsao, MD; George R. Blumenschein, MD; Mehmet Altan, MD; John V. Heymach, MD, PhD; James W. Welsh, MD; Suyu Liu, PhD; Zhongxing Liao, MD; Roberto F. Casal, MD — The University of Texas MD Anderson Cancer Center

Patients who are candidates for re-irradiation are frequently limited to palliative radiation doses because of normal-tissue tolerance, and their recurrent tumors typically harbor the most radiation-resistant cells. Effective strategies to safely deliver radiotherapy doses capable of controlling recurrent tumors remain a significant unmet need in this setting.

“Recurrence within a previously irradiated field is one of the least forgiving problems in thoracic oncology,” said Saumil Gandhi, MD, PhD, Department of Thoracic Radiation Oncology, Division of Radiation Oncology at UT MD Anderson. “The normal tissue near the tumor has already received a full course of radiation, so the dose that can delivered safely during a second course is limited. Additionally, the disease that returns is often more radioresistant because it survived radiation the first time. In this study, JNJ-1900 (NBTXR3) was delivered without dose-limiting toxicities, and we observed clinically meaningful local control at a substantially lower re-irradiation dose. These findings warrant evaluation in a randomized trial.”

Results from the pooled dose-escalation and expansion phases showed that all 24 patients completed treatment with JNJ-1900 (NBTXR3) plus re-irradiation with no dose-limiting toxicities. Investigators reported no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3) or to the injection procedure.

Grade 3 radiotherapy-related adverse events occurred in 33% of patients (n=8), and Grade 5 radiotherapy-related adverse events in 8% (n=2). The recommended Phase 2 dose was established at 33% of gross tumor volume.

At a median follow-up of 12 months (data cutoff: August 2026) the one-year locoregional control rate was 79%. One-year local progression-free survival (“LPFS”) was 61% (median 13.6 months), and one-year overall survival (“OS”) was 70% (median 14.8 months). Investigators concluded that JNJ-1900 (NBTXR3) may permit clinically meaningful local control using a substantially lower re-irradiation dose.

“The Nanobiotix team is encouraged by these full-cohort findings in one of the most difficult settings in lung cancer,” said Louis Kayitalire, MD, Chief Medical Officer of Nanobiotix. “If a physics-based approach can improve local control in tissue that has already failed radiation, and do so at a reduced dose, then the conditions in earlier settings, where full-dose radiotherapy reaches previously untreated tissue, could be even more favorable. We look forward to further evaluation in additional patients enrolled to this study and across indications.”

Enrollment in both the dose-escalation and expansion parts of the study is complete per protocol. Following the encouraging findings, additional patient enrollment in this study is planned.

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft tissue sarcoma study sponsored by Nanobiotix in 2018.

Radiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.

In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. Studies being led by Johnson & Johnson include NANORAY-312 (NCT04892173), a global, randomized Phase 3 study in platinum-based chemotherapy-ineligible, locally advanced head and neck squamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label study in locally advanced head and neck squamous cell cancers; and CONVERGE (NCT06667908), a phase 2, randomized, open-label, active-controlled study in locally advanced and unresectable Stage III non-small cell lung cancer (NSCLC).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 2, 2025 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2024 universal registration document filed with the AMF on April 2, 2025 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2025 which are available on the SEC’s website at www.sec.gov and on the AMF’s website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com  Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com

Attachment

• PR_MDA_NSCLC_ReRT_WCLC_2026__VF (https://ml.globenewswire.com/Resource/Download/77b58adf-135a-40bf-8717-123226be4616)

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 14.1 KB